Registry following transcranial pulse stimulation treatment for Alzheimer's disease in Germany
Collects safety and effect data on pulse wave stimulation for people with Alzheimer's disease.
Plain-language title generated from the registry record
Registry title: German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation
Key facts
- Where
- Bonn, Kempen, Neuss, Oldenburg, Potsdam, and Ulm, GermanySee the 6 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT06313944, who can take part
Where in Germany
- Universitätsklinikum Bonn - Klinik für Parkinson, Schlaf- und BewegungsstörungenBonn, GermanyNot yet recruiting
- Hospital zum Heiligen Geist GmbH & Co KG Klinik für Neurologie und NeurorehabilitationKempen, GermanyNo longer taking part
- Neurologische Praxis Prof. WojteckiNeuss, GermanyTaking people
- Evangelische Krankenhausstiftung Oldenburg - Universitätsklinik für NeurologieOldenburg, GermanyTaking people
- Ernst von Bergmann Klinikum - Klinik für Neurologie und Klinische NeuropsychologiePotsdam, GermanyTaking people
- Praxis Dr. SchwarzUlm, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Heinrich-Heine University, Duesseldorf
- Trial code
- NCT06313944
- Record updated
- 13 October 2026
- Original description
This study will primarily investigate the safety and secondarily the effect and applicability of Transcranial Pulse Wave Stimulation (TPS) for the treatment of Alzheimer's disease in the context of a PMCF study (Post-Market Clinical Follow-up). The multicenter, prospective data collection should help to optimize the stimulation protocol, as well as to record frequent to occasional adverse effects of the product and cognitive, affective and subjective scores.Read full original descriptionShow less
German (GE) Multicenter Prospective Data Collection (Registry) on Treatment With Transcranial Pulse Wave Stimulation (TPS) in Patients With Alzheimer's Disease (A)
This study will primarily investigate the safety and secondarily the effect and applicability of Transcranial Pulse Wave Stimulation (TPS) for the treatment of Alzheimer's disease in the context of a PMCF study (Post-Market Clinical Follow-up). The multicenter, prospective data collection should help to optimize the stimulation protocol, as well as to record frequent to occasional adverse effects of the product and cognitive, affective and subjective scores.
Inclusion: Age = 18 to 85 ii. N>=100, clinical Alzheimer's syndrome, defined by a gradually progressive change in memory function (for severity using the MMSE as a screening tool) and impairment of activities of daily living for more than six months iii. MRI scan, in vivo evidence from CSF and/or PET using the NIA-AA criteria, which categorize the underlying pathological processes based on biomarkers, should be added if possible, but are optional. These biomarkers are categorized as ß-amyloid deposition, pathological tau and neurodegeneration [AT(N)], which can be detected on imaging and in biofluids. If possible, patients with Alzheimer's disease (AD) or Alzheimer's continuum should be included; TPS treatment in a center of a neurological or psychiatric specialist and performed under supervision of a specialist.
Exclusion: Relevant intracerebral pathologies not related to Alzheimer's disease, such as vascular encephalopathy Fazekas grade 3, tumors, vascular malformations, pregnancy, metal implants, CAA according to Boston criteria, Z.n. or during antibody therapy ii. Blood coagulation disorders or oral anticoagulation iii. Epilepsy iv. Medical conditions leading to non-compliance with the protocol.